https://www.vesaliusbiocapital-3.com/first-close-fund-3.html2017-05-18T12:29:28+02:00https://www.vesaliusbiocapital-3.com/new-fund-national-promotional-bank.html2017-09-19T12:10:27+02:00https://www.vesaliusbiocapital-3.com/sword-health-funding.html2018-04-16T12:33:28+02:00https://www.vesaliusbiocapital-3.com/forendo-pharma.html2018-09-04T09:52:24+02:00https://www.vesaliusbiocapital-3.com/mecuris.html2019-01-16T17:49:48+01:00https://www.vesaliusbiocapital-3.com/forendo.html2019-03-05T10:09:46+01:00https://www.vesaliusbiocapital-3.com/mercuris-denise-schindler.html2019-04-15T15:45:51+02:00https://www.vesaliusbiocapital-3.com/sword-health-raises-funding.html2019-04-16T17:59:12+02:00https://www.vesaliusbiocapital-3.com/final-close-fund.html2019-06-25T09:33:22+02:00https://www.vesaliusbiocapital-3.com/mercuris-schneider-littfeld-advisory-board.html2019-07-04T09:39:26+02:00https://www.vesaliusbiocapital-3.com/investment-dearhealth.html2019-07-18T17:29:55+02:00https://www.vesaliusbiocapital-3.com/sunstone-joins-syndicate.html2019-07-19T13:45:13+02:00https://www.vesaliusbiocapital-3.com/forendo-phase-1b-proof-study.html2019-08-16T14:43:48+02:00https://www.vesaliusbiocapital-3.com/mercuris-best-medtech-startups-listed.html2019-08-26T11:12:36+02:00https://www.vesaliusbiocapital-3.com/tonic-app-finance.html2019-08-27T06:41:38+02:00https://www.vesaliusbiocapital-3.com/omeicos-dr-russel-ceo.html2019-09-01T15:28:11+02:00https://www.vesaliusbiocapital-3.com/deal-forendo-novartis.html2019-12-11T16:24:59+01:00https://www.vesaliusbiocapital-3.com/3d-druck-medizintechnik.html2019-12-16T11:57:13+01:00https://www.vesaliusbiocapital-3.com/mercuris-new-funding.html2020-01-13T07:26:05+01:00https://www.vesaliusbiocapital-3.com/peter-froehlingsdorf.html2020-02-10T12:44:42+01:00https://www.vesaliusbiocapital-3.com/oncodna-financing-series-b.html2020-02-13T14:24:24+01:00https://www.vesaliusbiocapital-3.com/prosthetic-feet-3d-printer.html2020-02-20T21:34:24+01:00https://www.vesaliusbiocapital-3.com/sword-health-raises-funding-17m.html2020-02-27T12:54:10+01:00https://www.vesaliusbiocapital-3.com/dearhealth-chronic-disease-management-platform.html2020-05-27T12:16:01+02:00https://www.vesaliusbiocapital-3.com/sword-health-leadership-appointments.html2020-06-15T06:12:40+02:00https://www.vesaliusbiocapital-3.com/sword-health-concoerdia-plan-services.html2020-06-17T06:57:05+02:00https://www.vesaliusbiocapital-3.com/takeover-bid-oncodna-on-integragen.html2020-07-09T08:20:58+02:00https://www.vesaliusbiocapital-3.com/forendo-dr-csimma-board-of-directors.html2020-09-09T07:53:11+02:00https://www.vesaliusbiocapital-3.com/topas-therapeutics-klaus-martin-ceo.html2020-10-19T09:43:33+02:00https://www.vesaliusbiocapital-3.com/topas-therapeutics-raises-22million.html2020-10-19T12:42:31+02:00https://www.vesaliusbiocapital-3.com/ucla-health-app.html2020-11-04T15:45:23+01:00https://www.vesaliusbiocapital-3.com/catalym-raises-eur50-million.html2020-11-09T16:16:27+01:00https://www.vesaliusbiocapital-3.com/dearhealth-winner-ai-award.html2020-11-26T13:22:02+01:00https://www.vesaliusbiocapital-3.com/oncodna-wins-biotech-award.html2020-11-27T15:15:28+01:00https://www.vesaliusbiocapital-3.com/catalym-clinical-trial.html2021-01-28T09:57:46+01:00https://www.vesaliusbiocapital-3.com/sword-health-25-million.html2021-02-03T05:52:39+01:00https://www.vesaliusbiocapital-3.com/catalym-key-management-and-board-changes.html2021-02-27T13:26:32+01:00https://www.vesaliusbiocapital-3.com/rejuvenate-biomed-secures-3-2m.html2021-03-02T17:06:56+01:00https://www.vesaliusbiocapital-3.com/forendo-completion-phase-1-studies.html2021-03-03T06:04:02+01:00https://www.vesaliusbiocapital-3.com/dearhealth-recruits-senior-executives.html2021-03-30T12:17:52+02:00https://www.vesaliusbiocapital-3.com/caresyntax-raises-100million.html2021-05-03T15:44:23+02:00https://www.vesaliusbiocapital-3.com/catalym-dr-lhuiller-ceo.html2021-05-04T11:58:40+02:00https://www.vesaliusbiocapital-3.com/dearhealth-ce-marking.html2021-06-10T14:20:18+02:00https://www.vesaliusbiocapital-3.com/swordhealth-raises-85m.html2021-07-06T07:48:47+02:00https://www.vesaliusbiocapital-3.com/topas-raises-40m.html2021-07-28T20:19:14+02:00https://www.vesaliusbiocapital-3.com/oncodna-and-sophia-genetics.html2021-09-27T14:06:19+02:00https://www.vesaliusbiocapital-3.com/rejuvenate-biomed-15-7-million.html2021-10-12T15:01:37+02:00https://www.vesaliusbiocapital-3.com/organon-to-acquire-forendo-pharma.html2021-11-11T11:46:53+01:00https://www.vesaliusbiocapital-3.com/sword-health-valued-2-billion.html2021-11-22T14:38:09+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics.html2022-02-16T10:24:10+01:00https://www.vesaliusbiocapital-3.com/topas-appoints-cristina-de-min.html2022-02-15T11:22:54+01:00https://www.vesaliusbiocapital-3.com/catalym-antibody-gdf-15-ctl-002.html2022-03-07T08:39:05+01:00https://www.vesaliusbiocapital-3.com/scenic-biotech-announces-31-million.html2022-03-11T09:11:05+01:00https://www.vesaliusbiocapital-3.com/rejuvenate-clinical-trial.html2022-03-29T14:59:41+02:00https://www.vesaliusbiocapital-3.com/oncodna-synlab-biomarker-testing-cancer-therapy.html2022-03-29T15:24:18+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-clinical-study.html2022-05-31T08:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-fda-ind-clearance.html2022-09-26T15:13:40+02:00https://www.vesaliusbiocapital-3.com/dear-health-ovarian-cancer.html2022-10-26T14:28:22+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-partnership.html2022-10-31T10:00:01+01:00https://www.vesaliusbiocapital-3.com/catalym-eur-50-million-financing.html2022-11-22T19:01:42+01:00https://www.vesaliusbiocapital-3.com/catalym-expands-visugromab-development.html2022-12-14T07:52:34+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-positive-phase-1-data.html2023-01-24T07:48:56+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-fast-track-designation-anti-bkv.html2023-05-02T10:25:52+02:00https://www.vesaliusbiocapital-3.com/topas-therapeutics-phase2a-clinical-trial-tpm502.html2023-05-25T06:43:00+02:00https://www.vesaliusbiocapital-3.com/catalym-announces-initial-data.html2023-06-06T11:04:33+02:00https://www.vesaliusbiocapital-3.com/memotherapeutics-pivotal-phase.html2023-06-22T07:00:00+02:00https://www.vesaliusbiocapital-3.com/oncodna-closing-round-c-financing.html2023-07-03T11:47:56+02:00https://www.vesaliusbiocapital-3.com/catalym-nature-communications.html2023-07-20T08:00:00+02:00https://www.vesaliusbiocapital-3.com/rejuvenate-biomed-positive-results.html2023-10-04T08:00:00+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-chf-25-million-series-c-financing.html2023-11-02T08:00:00+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-ceo-erik-van-den-berg.html2023-11-16T08:00:00+01:00https://www.vesaliusbiocapital-3.com/catalym-positive-phase-2a-outcome.html2023-12-06T14:00:00+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-management-team.html2024-02-05T08:00:00+01:00https://www.vesaliusbiocapital-3.com/caresyntax-fierce-healthcares-fierce-15-2024.html2024-02-20T06:14:15+01:00https://www.vesaliusbiocapital-3.com/rejuvenate-therapeutic-potential-jx-01.html2024-02-22T07:01:17+01:00https://www.vesaliusbiocapital-3.com/mecuris-ottobock-technology-transfer.html2024-02-29T12:00:00+01:00https://www.vesaliusbiocapital-3.com/scenic-biotech-research-collaboration-bristol-myers-squib.html2024-04-30T16:18:33+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-series-c-financing.html2024-05-07T08:00:00+02:00https://www.vesaliusbiocapital-3.com/topas-therapeutics-hugo-fry-ceo.html2024-05-07T08:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-impressive-and-lasting-responses-to-cancer-patients.html2024-06-02T18:30:00+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-paul-carter-chairperson.html2024-07-08T15:52:35+02:00https://www.vesaliusbiocapital-3.com/catalym-new-financing.html2024-07-12T13:29:31+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-alex-bastian.html2024-08-21T21:15:25+02:00https://www.vesaliusbiocapital-3.com/topas-therapeutics-positive-topline-results.html2024-10-15T11:56:29+02:00https://www.vesaliusbiocapital-3.com/phase-2-study-in-copd-related-sarcopenia.html2024-10-28T14:07:37+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-phase-2-trial-potravitug.html2024-11-01T10:00:00+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-frits-van-alphen-cdo.html2024-11-04T12:00:00+01:00https://www.vesaliusbiocapital-3.com/catalym-scott-clarke-as-ceo.html2025-01-11T12:34:47+01:00https://www.vesaliusbiocapital-3.com/dearhealth-sluit-zich-aan-bij-topicus.html2025-04-05T12:00:00+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-study-transcytosis.html2025-06-11T15:26:20+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-on-world-transplant-congress.html2025-06-20T07:02:37+02:00https://www.vesaliusbiocapital-3.com/scenic-biotech-nature-publication.html2025-05-07T00:00:00+02:00https://www.vesaliusbiocapital-3.com/rejuvenate-biomed-doses-first-patient-phase-ii-trial-copd-related-muscle-weakness-and-sarcopenia.html2025-05-19T09:00:00+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-phase-ii-trial-results-for-potravitug.html2025-07-25T11:00:00+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-phase-i-study.html2025-08-19T11:22:50+02:00https://www.vesaliusbiocapital-3.com/scenic-license-and-research-agreement-with-alnylam.html2025-08-26T09:00:00+02:00https://www.vesaliusbiocapital-3.com/scenic-biotech-publishes-in-nature.html2025-09-03T09:00:00+02:00https://www.vesaliusbiocapital-3.com/scenic-biotech-appoints-dr-roland-w-buerli-as-cso.html2025-09-09T09:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-announces-leadership-changes.html2025-09-15T10:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-primary-results-bladder-cancer-trial-at-esmo.html2025-09-23T13:19:08+02:00https://www.vesaliusbiocapital-3.com/catalym-first-patient-dosed-nsclc.html2025-09-30T13:32:05+02:00https://www.vesaliusbiocapital-3.com/catalym-phase2-data-bladder-cancer.html2025-10-17T12:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-presents-long-term-phase1-2a-data.html2025-10-20T12:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-visugromab-at-sitc-2025.html2025-11-07T08:06:20+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-long-term-follow-up-data.html2025-11-07T11:39:44+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-orphan-designation-in-eu.html2025-12-18T13:52:40+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-bkpyv-infection-disease-burden-study.html2026-01-09T13:40:15+01:00https://www.vesaliusbiocapital-3.com/sword-health-acquires-kaia-health.html2026-01-28T10:00:00+01:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-collaboration-with-csl.html2026-02-09T12:19:31+01:00https://www.vesaliusbiocapital-3.com/catalym-visugromab.html2026-04-07T12:40:36+02:00https://www.vesaliusbiocapital-3.com/catalym-first-patient-dosed-in-phase23-vincit.html2026-04-23T13:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-christian-s-schade-chairman-of-board-of-directors.html2026-04-28T09:00:00+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-further-results-potravitug.html2026-06-05T08:00:00+02:00https://www.vesaliusbiocapital-3.com/catalym-peter-garcia-cfo.html2026-06-09T13:00:00+02:00https://www.vesaliusbiocapital-3.com/scenic-biotech-joins-lite-program.html2026-06-11T16:55:26+02:00https://www.vesaliusbiocapital-3.com/memo-therapeutics-complete-phase-2-data.html2026-06-18T11:15:15+02:00https://www.vesaliusbiocapital-3.com/ipsen-to-acquire-memo-therapeutics-ag.html2026-07-01T07:24:26+02:00https://www.vesaliusbiocapital-3.com/ipsen-completes-acquisition-of-memo-therapeutics-ag.html2026-07-22T12:00:00+02:00https://www.vesaliusbiocapital-3.com/sword-to-acquire-headspace.html2026-09-16T07:00:00+02:00